Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 6.35%15.06B | -3.08%14.16B | -10.02%4.03B | -6.67%3.18B | 11.22%3.8B | -4.75%3.14B | 17.72%14.61B | 25.62%4.48B | 22.93%3.41B | 12.12%3.42B |
| Cost of revenue | 5.33%11.03B | -3.18%10.48B | -12.40%2.93B | -7.91%2.31B | 9.83%2.84B | 0.63%2.4B | 16.26%10.82B | 24.96%3.34B | 11.88%2.51B | 15.04%2.59B |
| Gross profit | 9.26%4.02B | -2.79%3.68B | -3.05%1.11B | -3.20%871.07M | 15.57%961.27M | -18.75%743.47M | 22.10%3.79B | 27.57%1.14B | 69.63%899.88M | 3.93%831.79M |
| Operating expense | 5.01%2.45B | -2.65%2.33B | 2.33%604.02M | -8.16%563.15M | -0.65%578.45M | -3.84%585.07M | 6.96%2.39B | 2.90%590.26M | 6.34%613.18M | 6.56%582.25M |
| Staff costs | 5.10%1.19B | 1.35%1.14B | ---- | ---- | ---- | ---- | 7.23%1.12B | ---- | ---- | ---- |
| Selling and administrative expenses | 16.44%532.72M | -6.69%457.49M | ---- | ---- | ---- | ---- | 6.00%490.28M | ---- | ---- | ---- |
| -Selling and marketing expense | ---- | --0 | ---- | ---- | ---- | ---- | -66.71%1.86M | ---- | ---- | ---- |
| -General and administrative expense | 16.44%532.72M | -6.33%457.49M | ---- | ---- | ---- | ---- | 6.88%488.42M | ---- | ---- | ---- |
| Research and development costs | -0.73%316.1M | -3.62%318.44M | ---- | ---- | ---- | ---- | 3.48%330.38M | ---- | ---- | ---- |
| Depreciation and amortization | -10.24%16.64M | -0.03%18.54M | ---- | ---- | ---- | ---- | -28.12%18.55M | ---- | ---- | ---- |
| -Depreciation | -10.24%16.64M | -0.03%18.54M | ---- | ---- | ---- | ---- | -28.12%18.55M | ---- | ---- | ---- |
| Other operating expenses | -3.00%388.87M | -7.78%400.9M | ---- | ---- | ---- | ---- | 12.63%434.7M | ---- | ---- | ---- |
| Operating profit | 16.57%1.58B | -3.04%1.35B | -8.81%503.12M | 7.40%307.92M | 53.41%382.82M | -48.34%158.39M | 61.29%1.39B | 71.58%551.76M | 721.06%286.7M | -1.73%249.54M |
| Net non-operating interest income (expenses) | -27.37%-7.62M | -42.73%-5.98M | -264.19%-4.57M | 72.47%-207K | 35.40%-918K | 62.04%-290K | 14.05%-4.19M | -156.92%-1.25M | -2.59%-752K | 72.18%-1.42M |
| Non-operating interest income | -47.73%1.49M | 71.86%2.86M | 16.31%549K | 106.17%769K | 97.20%775K | 80.00%765K | -15.41%1.66M | 13.19%472K | -25.55%373K | -16.56%393K |
| Non-operating interest expense | 69.61%9.11M | -8.22%5.37M | -4.46%1.65M | -13.24%976K | -6.67%1.69M | -11.27%1.06M | -14.44%5.85M | -4.54%1.73M | -8.83%1.13M | -8.61%1.81M |
| Total other finance cost | ---- | --3.47M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net investment income | 9.33%65.29M | 9.57%59.72M | 236.63%1.64M | 18.27%22.88M | 105.44%4.08M | -4.79%31.13M | -0.94%54.51M | -50.41%486K | -8.47%19.34M | -66.65%1.99M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | -99.92%46K | 340.84%60.08M | 3,186.71%61.59M | -102.80%-405K | 100.12%33K | 92.24%-1.14M | -176.60%-24.95M | -87.69%1.87M | -60.36%14.46M | -382.91%-26.6M |
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 109.71%23.33M | -77.03%11.13M | -66.65%17.07M | -89.33%-23.27M | 99.79%19.09M | -1.76M | 727.02%48.44M | 996.83%51.17M | -12.29M | 9.56M |
| Less:Other special charges | -109.71%-23.33M | 77.03%-11.13M | 66.65%-17.07M | 89.33%23.27M | ---19.09M | --1.76M | -727.02%-48.44M | -996.83%-51.17M | --12.29M | ---- |
| Other non-operating income (expenses) | -55.30%23.42M | -15.74%52.39M | -486.40%-7.53M | 4.32%50.61M | 75.62%5.97M | -59.84%3.34M | 60.62%62.18M | -91.08%1.95M | 446.44%48.52M | 32.18%3.4M |
| Income before tax | 9.88%1.68B | -0.07%1.53B | -5.72%571.32M | 0.43%357.52M | 73.84%411.08M | -42.90%189.66M | 56.44%1.53B | 70.16%605.98M | 1,924.90%355.98M | -11.35%236.46M |
| Income tax | -2.46%463.22M | 3.60%474.93M | -4.20%176.82M | 1.73%107.92M | 87.90%123.51M | -34.65%66.68M | 53.68%458.43M | 89.54%184.58M | 847.21%106.09M | -26.81%65.73M |
| Net income | 15.44%1.22B | -1.63%1.05B | -6.38%394.5M | -0.11%249.6M | 68.43%287.57M | -46.56%122.99M | 57.65%1.07B | 62.87%421.39M | 3,816.17%249.89M | -3.51%170.73M |
| Net income continuous operations | 15.44%1.22B | -1.63%1.05B | -6.38%394.5M | -0.11%249.6M | 68.43%287.57M | -46.56%122.99M | 57.65%1.07B | 62.87%421.39M | 3,816.77%249.89M | -3.51%170.73M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 15.44%1.22B | -1.63%1.05B | -6.38%394.5M | -0.11%249.6M | 68.43%287.57M | -46.56%122.99M | 57.65%1.07B | 62.87%421.39M | 3,816.17%249.89M | -3.51%170.73M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 15.44%1.22B | -1.63%1.05B | -6.38%394.5M | -0.11%249.6M | 68.43%287.57M | -46.56%122.99M | 57.65%1.07B | 62.87%421.39M | 3,816.17%249.89M | -3.51%170.73M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 15.42%118.73 | -1.64%102.87 | -6.42%38.47 | -0.08%24.35 | 68.37%28.05 | -46.55%12 | 57.63%104.59 | 62.88%41.11 | 3,830.65%24.37 | -3.53%16.66 |
| Diluted earnings per share | 15.42%118.73 | -1.64%102.87 | -6.42%38.47 | -0.11%24.3423 | 68.40%28.05 | -46.55%12 | 57.63%104.59 | 62.87%41.1086 | 3,830.65%24.37 | -3.52%16.6563 |
| Dividend per share | 118.75%35 | 6.67%16 | 6.67%16 | 0 | 10 | 0 | 15 | 15 | 0 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |